Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.53, $0.04 better than the analyst estimate of $0.49. Revenue for the quarter came in at $3.6 billion versus the consensus estimate of $3.5 billion.

GUIDANCE:

Boston Scientific sees Q3 2023 EPS of $0.46-$0.48, versus the consensus of $0.48.

Boston Scientific sees FY2023 EPS of $1.96-$2.00, versus the consensus of $1.95.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.